Theratechnologies Profit Margin 2011-2021 | THTX
Current and historical gross margin, operating margin and net profit margin for Theratechnologies (THTX) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Theratechnologies net profit margin as of August 31, 2021 is -39%.
|Theratechnologies Annual Profit Margins
|Theratechnologies Quarterly Profit Margins
||Medical - Biomedical and Genetics
Theratechnologies, Inc. is a pharmaceutical company focusing on the development of therapeutic peptide products with an emphasis on growth-hormone releasing factor peptides. It's main product EGRIFTA is used for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy which is marketed primarily in the United States, Latin America, Africa, the Middle East, Europe, Russia, South Korea, Taiwan, and Thailand. Theratechnologies, Inc. is headquartered in Montreal, Canada.